Novartis buys Takeda’s dry eye drug for $3.4 bln
Posted on May 14, 2019
Swiss drugmaker Novartis AG said on Wednesday it agreed to acquire Takeda Pharmaceutical Company Ltd’s dry eye drug Xiidra for an upfront payment of $3.4 billion to expand its portfolio of eye care medicines.
The deal includes potential milestone payments of up to $1.9 billion and is expected to close in the second half of 2019.
Related Topics and Keywords
Subscribe to our FREE newsletter